Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

In up to 30% of non-small cell lung cancer (NSCLC) patients, the oncogenic driver of tumor growth is a constitutively activated epidermal growth factor receptor (EGFR). Although these patients gain great benefit from treatment with EGFR tyrosine kinase inhibitors, the development of resistance is in...

Full description

Bibliographic Details
Main Authors: Julia Schueler, Cordula Tschuch, Kerstin Klingner, Daniel Bug, Anne-Lise Peille, Leanne de Koning, Eva Oswald, Hagen Klett, Wolfgang Sommergruber
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cells
Subjects:
NSCLC
acquired resistance
EGFR inhibition
PDX
reverse phase protein array
whole exome sequencing
Online Access:https://www.mdpi.com/2073-4409/8/7/740

Internet

https://www.mdpi.com/2073-4409/8/7/740

Similar Items